Vericel (VCEL) Work In Process (2014 - 2026)
Vericel (VCEL) posted Work In Process of $1.6 million for Q2 2026, up 5.04% sequentially from $1.5 million in Q1 2026, and down 22.93% YoY from $2.1 million in Q2 2025.
Vericel (VCEL) Work In Process (2014 - 2026) Analysis & Trends
Vericel has reported Work In Process for 13 years, with the latest figure at $1.6 million in Q2 2026.
- Quarterly Work In Process fell 22.93% year-over-year to $1.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 million (down 22.93% YoY) and the FY2025 annual result came in at $1.6 million, up 0.83% from the prior year.
- Work In Process rose to $1.6 million in Q2 2026 per VCEL's latest filing, from $1.5 million in the prior quarter.
- Over five years, Work In Process peaked at $2.1 million in Q2 2025 and troughed at $683000.0 in Q2 2022.
- A 5-year average of $1.3 million and a median of $1.5 million in 2025 frame the typical range for Work In Process.
- The sharpest annual moves came in 2024 and 2026: Work In Process surged 107.07% in 2024, then slipped 22.93% in 2026.
- Over 5 years, Work In Process stood at $832000.0 in 2022, then soared by 45.43% to $1.2 million in 2023, then rose by 29.83% to $1.6 million in 2024, then climbed by 0.83% to $1.6 million in 2025, then slipped by 0.06% to $1.6 million in 2026.
- According to Business Quant data, Work In Process over the past three periods registered $1.6 million, $1.5 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 967,000.00 |
| Jun 30, 2023 | 863,000.00 |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 832,000.00 |
| Sep 30, 2022 | 883,000.00 |
| Jun 30, 2022 | 683,000.00 |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 644,000.00 |
| Sep 30, 2021 | 976,000.00 |